Literature DB >> 31306525

Endoscopic submucosal dissection is associated with less pathologic uncertainty than endoscopic mucosal resection in diagnosing and staging Barrett's-related neoplasia.

Alexander Podboy1, Kevin Sohail Kolahi2, Shai Friedland1,3, Christine Y Louie2,4.   

Abstract

BACKGROUND & AIMS: Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have demonstrated similar efficacy in removal of neoplastic esophageal lesions. However, significant controversy exists over the preferred resection technique. Our primary aim was to compare the pathologic specimens produced via EMR and ESD and secondarily gauge their effect on clinical decision making and patient outcomes.
METHODS: Using a retrospective cohort study design, all esophageal Barrett's-associated neoplastic lesions resected by a single provider from 2012 to 2017 were reviewed. The pathology was re-reviewed by two blinded authors for diagnosis, margins, and adverse outcomes and recurrence rates were also collected.
RESULTS: Thirty-one EMR and 20 ESD cases were identified. Baseline demographics and lesion characteristics were similar. ESD produced more R0 resections and more en bloc resections compared to EMR. EMR produced more equivocal lateral (13/31, 41.9% vs 1/20, 5.0%) and vertical margins (13/31, 41.9% vs. 0/20, 0%, both P < 0.05). This led to an inability to reach a definitive diagnosis in 13/31 EMR vs 0/20 ESD pathology specimens (P = 0.003). Of the 13 EMR specimens with equivocal pathology, 11 were noted to have 'at least intramucosal adenocarcinoma'. Four of the 11 patients chose to undergo elective esophagectomy with final surgical pathology demonstrating ≤T1a disease in 2, and ≥T1b disease in two.
CONCLUSION: Compared to ESD, EMR was associated with greater pathologic uncertainty in Barrett's-associated neoplasia.
© 2019 Japan Gastroenterological Endoscopy Society.

Entities:  

Keywords:  Barrett's esophagus; endoscopic mucosal resection; esophageal adenocarcinoma

Mesh:

Year:  2019        PMID: 31306525     DOI: 10.1111/den.13487

Source DB:  PubMed          Journal:  Dig Endosc        ISSN: 0915-5635            Impact factor:   7.559


  6 in total

Review 1.  Today's Mistakes and Tomorrow's Wisdom in Endoscopic Treatment and Follow-Up of Barrett's Esophagus.

Authors:  Maximilien Barret
Journal:  Visc Med       Date:  2022-03-18

2.  Outcomes for endoscopic submucosal dissection of pathologically staged T1b esophageal cancer: a multicenter study.

Authors:  Abel Joseph; Peter V Draganov; Fauze Maluf-Filho; Hiroyuki Aihara; Norio Fukami; Neil R Sharma; Amitabh Chak; Dennis Yang; Salmaan Jawaid; John Dumot; Omar Alaber; Tiffany Chua; Rituraj Singh; Lady Katherine Mejia-Perez; Ruishen Lyu; Xuefeng Zhang; Suneel Kamath; Sunguk Jang; Sudish Murthy; John Vargo; Amit Bhatt
Journal:  Gastrointest Endosc       Date:  2022-02-22       Impact factor: 10.396

3.  Characteristics and Distribution of Surgical Diseases in North Korean Research Papers Published between 2006 and 2017.

Authors:  Yo Han Lee; Namkee Oh; Hyerim Kim; Shin Ha
Journal:  J Korean Med Sci       Date:  2021-03-29       Impact factor: 2.153

4.  Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review.

Authors:  Paul Doumbe-Mandengue; Anna Pellat; Benoit Terris; Frédéric Beuvon; Mahaut Leconte; Anthony Dohan; Stanislas Chaussade; Romain Coriat; Maximilien Barret
Journal:  Ann Gastroenterol       Date:  2022-05-12

5.  Efficacy and Safety Analysis of Submucosal Tunnel Endoscopic Resection for Submucosal Masses in Esophageal Muscularis Propria.

Authors:  Qianyi Liu; Weishan Ruan; Zhishang Liu; Jiefeng Li; Jiayan Li
Journal:  Comput Math Methods Med       Date:  2022-09-26       Impact factor: 2.809

6.  Comparative Outcomes of Cap Assisted Endoscopic Resection and Endoscopic Submucosal Dissection in Dysplastic Barrett's Esophagus.

Authors:  D Chamil Codipilly; Lovekirat Dhaliwal; Meher Oberoi; Parth Gandhi; Michele L Johnson; Ramona M Lansing; W Scott Harmsen; Kenneth K Wang; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2020-11-18       Impact factor: 11.382

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.